Confluence Investment Management LLC bought a new position in shares of Allergan PLC (NYSE:AGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 114,238 shares of the company’s stock, valued at approximately $26,310,000.

Other large investors have also modified their holdings of the company. Barnett & Company Inc. purchased a new stake in Allergan PLC during the first quarter valued at about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in Allergan PLC during the second quarter valued at about $125,000. Trust Co. of Vermont boosted its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the last quarter. Carroll Financial Associates Inc. boosted its stake in Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the last quarter. Institutional investors and hedge funds own 86.89% of the company’s stock.

Institutional Ownership by Quarter for Allergan PLC (NYSE:AGN)

Allergan PLC (NYSE:AGN) traded up 2.10% during trading on Tuesday, reaching $193.98. 1,669,833 shares of the company were exchanged. The stock has a market capitalization of $72.76 billion, a PE ratio of 5.44 and a beta of 1.08. Allergan PLC has a 52-week low of $184.50 and a 52-week high of $322.68. The firm’s 50 day moving average is $211.32 and its 200 day moving average is $233.30.

Allergan PLC (NYSE:AGN) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by $0.33. The company earned $3.62 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.48 EPS. Analysts expect that Allergan PLC will post $13.37 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.46%. This is a boost from Allergan PLC’s previous quarterly dividend of $0.05.

ILLEGAL ACTIVITY NOTICE: “Confluence Investment Management LLC Buys New Position in Allergan PLC (AGN)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/confluence-investment-management-llc-buys-new-position-in-allergan-plc-agn.html.

Several equities research analysts recently issued reports on the stock. Deutsche Bank AG set a $278.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research report on Saturday, October 15th. Vetr cut shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $235.38 price objective for the company. in a research report on Wednesday, November 9th. RBC Capital Markets restated an “outperform” rating and set a $300.00 price objective (down from $307.00) on shares of Allergan PLC in a research report on Wednesday, August 10th. Mizuho lowered their target price on shares of Allergan PLC from $299.00 to $293.00 and set a “buy” rating for the company in a research note on Tuesday, November 1st. Finally, Royal Bank Of Canada lowered their target price on shares of Allergan PLC from $300.00 to $279.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd. Seven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $289.11.

In related news, CEO Brent L. Saunders purchased 5,250 shares of the firm’s stock in a transaction on Monday, November 21st. The stock was purchased at an average price of $189.13 per share, for a total transaction of $992,932.50. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Maria Teresa Hilado purchased 1,422 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was bought at an average price of $210.64 per share, with a total value of $299,530.08. Following the acquisition, the chief financial officer now owns 12,659 shares in the company, valued at $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.

About Allergan PLC

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.